Introduction
============

For many years, the central nervous system (CNS) was considered to be immune privileged, neither susceptible nor contributing to infection/inflammation. It is now evident that CNS infection and neurological diseases trigger local inflammation and consequently activation of the immune response. In particular, the response to aggression is driven by the resident immune cells, the microglia distributed throughout the normal adult brain (Perry and Andersson, [@B90]; Nimmerjahn et al., [@B79]). Specifically, Alzheimer's disease (AD) is characterized by an inflammatory response to Amyloid-β (Aβ), inducing the activation of microglia and the recruitment of astrocytes to the sites where Aβ deposits occur (Sastre et al., [@B107]).

It is nowadays accepted that there is a dynamic microglia turnover in the brain and that microglia phenotype may change depending on aging, stage of the disease, and/or the presence of peripheral inflammation. In the brain there are also infiltrated macrophages, which play an essential role in the immune response.

The purpose of this review is first, to describe microglia as a cell of the immune system and the effects of peripheral inflammation on their activation. Secondly, our aim is to describe how this system is altered in a neurodegenerative disease, such as AD. Therefore, targeting microglia could serve as a potential therapy to treat AD patients.

Microglia the Innate Immunity Cell Component
============================================

Role of microglia and macrophages in the brain
----------------------------------------------

1.  -- Microglia represent around 10% of the cells in the nervous system. Although there are many theories concerning the origin of microglia, the general consensus today is its hematopoietic origin, derived from myeloid precursor cells, which enter the developing CNS during embryogenesis. Many questions remain about the recruitment and the life of the resident microglial in adult and aging brain (Chan et al., [@B16]).

    Microglia constitute the first line of defense against invading pathogens or other types of brain tissue injury. The general agreement is that microglia are the "sentinels" of the CNS. Their fundamental role is sensing both pathogen- and host-derived ligands within the CNS. By detecting the type of insult and consequently directing the innate to the adaptive immune response (e.g., removal of pathogen) they are fundamental to the resolution of inflammation. Under pathological situations, such as neurodegenerative disease, stroke, and tumor invasion, microglia become activated, surround damaged and dead cells, and clear cellular debris from the area, in analogy to phagocytic macrophages of the immune system (Fetler and Amigorena, [@B30]). This process plays a fundamental part in the reorganization of neural circuitry and repair mechanisms that arise following injury (Neumann et al., [@B76]; Neher et al., [@B75]). As part of a beneficial role microglial phagocytosis is a highly regulated process, with activated microglia expressing a wide, and redundant, variety of distinct receptors for the removal of pathogenic organisms, e.g., Toll-like receptors (TLRs; Neumann et al., [@B76]), or of apoptotic cell debris, e.g., CD36 and integrins (Napoli and Neumann, [@B74]; Lue et al., [@B61]). The microglial phagocytic response is thus a central part of the brain's defense mechanisms, and is a powerful contributor to the systems in place that ensure healthy neural function.

    Activated microglia also up-regulate other cell-surface receptors, including the major histocompatibility complex and complement receptors (Liu and Hong, [@B59]). Microglia experience dramatic morphological changes from ramified cells to activated amoeboid microglia (Kreutzberg, [@B52]). In addition, when microglia become activated they generate inflammatory mediators like cytokines, chemokines, prostaglandins, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), free radicals, and stimulating an adaptive immune response (Nimmerjahn et al., [@B79]; Ransohoff and Perry, [@B98]). The principal goals of such reactions include the repair and the restoration of the homeostasis, but complications often arise, resulting in detrimental effects and actual exacerbation of the occurring damage (Lehnardt, [@B56]).

2.  -- Apart from resident microglia, in the brain there are monocyte-derived macrophages (Schwartz and Shechter, [@B112]). Perivascular macrophages have a phagocytic role and are also implicated in the presentation of antigens to T cells that have been activated in the periphery, thereby facilitating the recognition of CNS antigens (Perry et al., [@B94]). The macrophage and microglia phenotype has been defined as M1 (classically activated via TLRs or interferon γ) and M2 (alternatively activated by interleukin 4 or interleukin 13), although it is assumed that a mixed population of both phenotypes exists (Cameron and Landreth, [@B13]; Perry et al., [@B94]). Because most techniques are unable to differentiate between both populations of microglia and macrophages in the brain, they are collectively referred as microglia. However, both microglia and infiltrated monocytes are not functionally redundant and have different properties, so they are both necessary to display functions such as brain repair.

Impact of peripheral inflammation in the brain
----------------------------------------------

Inflammation is a response mounted by the innate immune system in response to injury and infections in order to promote recovery. It was long thought that the brain was protected from systemic inflammation. However, growing evidence shows that systemic inflammatory stimuli, such as infection, also trigger a central response through microglia with consequent release of pro-inflammatory mediators (cytokines, lipid metabolites, free radicals). As part of the host-defense process, this stimulates autonomic, neuroendocrine, and behavioral responses that promote recovery. Under normal conditions the neuroinflammatory response resolves and microglia resume their "resting" state and role of monitoring the microenvironment. However, increasing experimental and clinical evidence indicates that systemic inflammation can worsen, or possibly trigger, neurological diseases (Weller et al., [@B124]; Ransohoff and Perry, [@B98]). These include stroke (McColl et al., [@B69]), Alzheimer's, prion, and motoneuron diseases (Nguyen et al., [@B77]; Perry, [@B89]; Rogers et al., [@B104]). Although the underlying mechanisms are not clear, mounting evidence suggests that microglia enter a primed/hyper-sensitive state in neurodegenerative conditions. This pre-disposes to an exaggerated production of toxic pro-inflammatory mediators in response to systemic inflammogens, thereby exacerbating neuronal loss (Streit et al., [@B119]; Godbout et al., [@B36]; Perry et al., [@B92]).

Understanding the routes of communication between peripheral immune responses and the brain has not been an easy challenge (Perry et al., [@B92]). The general belief is that immune messages are passed to the brain mainly through three different pathways: first, peripherally derived signals (mainly pro-inflammatory cytokines like IL-1β, TNF-α, and IL-6) and even pathogen-associated molecular patterns (PAMPs; for example the lipopolysaccharide (LPS), the main cell-wall component of Gram-negative bacteria) can access the nervous system through brain sites that lack a proper blood brain barrier (BBB), or through fenestrated capillaries (Rivest, [@B101]); secondly, on-going peripheral reactions can be sensed and transmitted to the brain via neural afferent pathways, mainly through the vagus nerve (Gao et al., [@B34]); lastly, the BBB itself, through the role of its numerous cellular components like endothelial cells and perivascular macrophages can sense circulating signals and respond to them, affecting behavior of neurons, astrocytes, and especially resident microglia population (Rivest, [@B102]; Figure [1](#F1){ref-type="fig"}).

![**Peripheral infection/inflammation causes the release of pro-inflammatory mediators, including cytokines (TNF-α, IL-1β, IL-6), arachidonic acid (AA), prostaglandins (PGs), and nitric oxide (NO) synthesis**. The brain also mounts an inflammatory response to systemic inflammation, as well as to local injury (neurodegeneration, trauma, stroke), with the microglial cells responding soonest and with production of the greatest amounts of pro-inflammatory mediators. However, the central response appears to be under tighter control than the peripheral response in that it is delayed and more modest, probably in order to avoid the dire consequences of a full-blown inflammatory response within the confines of the skull. Modified after Solito et al. ([@B116]).](fphar-03-00014-g001){#F1}

Microglia in aging
------------------

Despite the similarities with the innate immune response in the peripheral system, there are important differences with brain environment, where the microglia activity could be sometimes deleterious for the brain. This in-balance phenotype is determined by the fact that neuroinflammation may be chronic or acute (Colton, [@B18]). Both chronic low-grade peripheral inflammation (Ouchi et al., [@B82]) and microglial priming/hypersensitivity are associated with aging.

It is well known that microglia exhibit significant phenotypic changes during normal aging. Microglia cells from both aged humans and rodents show profoundly altered morphology, characterized by dystrophic processes, and abnormal clustering (Perry et al., [@B91]; Streit et al., [@B118]). These changes in morphology are accompanied by increased expression of activation markers such as MHCII and RAGE (Perry et al., [@B93]), raised basal production of the pro-inflammatory cytokines TNFα, IL-6, and IL-1β (Ye and Johnson, [@B131]; Xie et al., [@B128]; Sierra et al., [@B115]), and hyper-responsiveness to inflammatory stimulation (Njie et al., [@B80]), together suggesting that microglia become progressively dysfunctional with age. A likely explanation for this fact lies in the loss of endogenous factors which would normally control/drive prevent excessive microglial activation, and promote the beneficial, anti-inflammatory, phenotype. We could further hypothesize that microglia turnover with aging is reduced and that newly attracted monistic cells may acquire a wrong phenotype once enriched the brain environment (Kofler and Wiley, [@B51]).

In summary, microglial activation presents a double-edged sword: from one side we can define it as neuroprotective, forming the first line of defense in the CNS; from the other, it can become a neurodegenerative force, when its power is excessive and to represent risk factors for developing age-associated neurodegenerative disease (AD), contributing to the worsening of symptoms that occur after systemic infection (Perry et al., [@B92]). Understanding the shift between these two opposite and the changes that occurring with aging will allow us to minimize the harmful and capitalize the beneficial effects and consequently the treatment of neurodegenerative diseases (Yong and Rivest, [@B132]).

Microglia in Alzheimer's Disease
================================

Implications of AD pathogenesis in microglia activation
-------------------------------------------------------

Inflammation has been implicated in neuronal damage, increased Aβ generation, increased phosphorylation of tau, and cognitive impairment in AD. Cause or consequence of disease progression is still not clear. Clinical work and studies in animal models suggest that microglial activation precede amyloid plaques and tangles formation (Griffin et al., [@B38]; Heneka et al., [@B40]) while PET studies have reported inflammatory changes in one-third of amnestic mild cognitive impairment (MCI; Cagnin et al., [@B12]; Okello et al., [@B81]).

Many of the cytokines and chemokines secreted by microglia such as IL-1β, IL-6, TNF-α, IL-8, TGF-β, and macrophage inflammatory protein-1α (MIP-1α) have been found to have altered expression in AD patients compared to control individuals (Sastre et al., [@B107]). Animal models of AD, including the APP transgenic line Tg2567 carrying the Swedish mutation, also show elevated levels for TNF-α, IL-1β, IL-1α, chemoattractant protein-1, COX-2, and complement component 1q (Benzing et al., [@B9]; Matsuoka et al., [@B67]). In addition, an increased risk of AD has been associated with several polymorphisms of pro-inflammatory genes, including IL-1 (Nicoll et al., [@B78]), IL-6 (Capurso et al., [@B14]), TNF-α (McCusker et al., [@B70]; Perry et al., [@B88]), and α1-antichymotrypsin (Kamboh et al., [@B48]).

Amyloid peptides and their precursor protein (APP) are strong glial activators (Barger and Harmon, [@B7]) and knockdown of APP gene and its proteolytic products delay and decrease microglial activation (DeGiorgio et al., [@B24]). The extent of astrocytosis and microglial activation is directly dependent on the amyloid load, and treatment with β-sheet breaker peptides leads to reduced brain inflammation (Permanne et al., [@B86]). Aβ is able to activate a NFκB-dependent pathway that is required for cytokine production (Combs et al., [@B20]). In addition, the C-terminal (CT) 100 amino acids of βAPP, which is also present in senile plaques, can induce gliosis and neuronal death. CT100 exposure results in activation of mitogen-activated protein kinase (MAPK) pathways as well as NFκB (Bach et al., [@B5]). At the same time, inflammation may increase Aβ generation by affecting the transcription of the β-secretase (BACE1), the main enzyme responsible for Aβ generation (Sastre et al., [@B108], [@B110]), therefore creating a feed-forward cycle.

In addition, neuroinflammation participates in tau-mediated neurodegeneration (Jaworski et al., [@B46]). Animal models of tauopathy such as the P301S tau transgenic mice exhibit accumulation of activated microglial cells around tau-positive nerve cells (Yoshiyama et al., [@B133]). Eventually, pro-inflammatory cytokines are also able to modify the activity of kinases involved in Tau phosphorylation (Arnaud et al., [@B4]). Products of inflammation might change the substrate specificity of kinases/phosphatases leading to tau phosphorylation at pathological sites. It was shown recently that inflammation induced by infection increased GSK3 activity in the triple-transgenic mouse model of AD, associated with a shift of tau from the detergent-soluble to the detergent-insoluble fraction (Sy et al., [@B120]).

On the other hand, other proteins involved in AD, such as presenilin, have been implicated in inflammation. Presenilin conditional knockout mice present differential up-regulation of inflammatory markers in the cerebral cortex, such as strong microglial activation, and elevated levels of glial fibrillary acidic protein (GFAP), complement component C1q, and cathepsin S (Beglopoulos et al., [@B8]). In fact, γ-secretase inhibitors have been reported to impair microglial activity as measured in gene expression, protein levels, and migration ability, which resulted in a reduction of soluble β-amyloid phagocytosis. Moreover, microglia deficient in presenilin 1 and 2 showed impairment in phagocytosis of soluble β-amyloid (Farfara et al., [@B28]).

Mechanisms of Aβ-induced microglial activation
----------------------------------------------

As indicated above, Aβ is able to bind and activate microglia. The mechanism of action for this is through interaction with pattern recognition receptors (PRRS). Microglia express many PRRs (Farina et al., [@B29]; Falsig et al., [@B26]), which recognize and bind to both PAMPs, or danger-associated molecular patterns (DAMPs), such as Aβ (Salminen et al., [@B105]). Interaction of microglia with Aβ, via PRRs provokes their inflammatory actions.

### Toll-like receptors

Toll-like receptors are a type-1 integral glycoproteins (Pancer and Cooper, [@B84]; Miyake, [@B72]). Among the cell-surface TLRs, TLR2 and 4 can recognize Aβ (Carty and Bowie, [@B15]). Several studies have confirmed that TLR4 mediates microglial-induced neurotoxicity both *in vivo* and *in vitro* (Lehnardt et al., [@B57]; Walter et al., [@B122]).

Toll-like receptor activation is regulated by co-receptors, including MD-2, CD14, and CD36 (Akashi-Takamura and Miyake, [@B1]). Research using knockout mice for TLR4 or TLR2 demonstrated an increase in Aβ deposition and acceleration in cognitive decline (Tahara et al., [@B121]; Richard et al., [@B100]). These results suggest that TLR2 and TLR4 may be involved in Aβ clearance *in vivo* and hence provide neuroprotection in AD. In fact, it was shown that response of microglial cells to fibrillar forms of Aβ requires the participation of TLRs and the co-receptor CD14 (Reed-Geaghan et al., [@B99]). However, microglia internalize soluble Aβ through a non-saturable, fluid phase macropinocytic mechanism that is distinct from phagocytosis and receptor-mediated endocytosis (Mandrekar et al., [@B65]).

### Receptor for advanced end glycation products (RAGE)

RAGE is a member of the immunoglobulin superfamily of cell-surface proteins (Schmidt et al., [@B111]; Chavakis et al., [@B17]; Bierhaus et al., [@B10]). It is a multiligand receptor, which recognizes Aβ peptides and fibrils (Knapp and Prince, [@B50]). Interestingly, RAGE-expressing microglia are upregulated in AD, and microglial RAGE is reported to mediate the pro-inflammatory effects of Aβ (Yan et al., [@B129]; Lue et al., [@B62]; Arancio et al., [@B3]). This is supported by recent work whereby it was demonstrated in transgenic AD models that the interaction of microglial RAGE with Aβ activates signal transduction cascades (MAP kinase, p38, and ERK1/2), enhances cytokines production (IL-β and TNF-α), and accelerates or amplifies the inflammatory response, leading to recruitment or activation of microglia and astrocytes (Fang et al., [@B27]).

### Scavenger receptors

Scavenger receptor (SR) type-A (SR-A), type B1 (SR-B1), CD36, and CD40 are established receptors for insoluble fibrillar Aβ aggregates, and are expressed by activated microglia, mediating the endocytosis of oligomeric and fibrillar Aβ (El Khoury et al., [@B25]; Paresce et al., [@B85]; Coraci et al., [@B21]; Husemann et al., [@B44]). Microglial adherence via SR-A binding to fibrillar Aβ leads to microglial immobilization, production of ROS, secretion of cytokines such as TNF-α and complement proteins (El Khoury et al., [@B25]).

### Formyl peptide receptors

Aβ can also bind to members of the seven-transmembrane G protein coupled receptors known as formyl peptide receptors (FPRs; Le et al., [@B54]). FPR, FPR-like 1 (FPRL-1), and FPR-like 2 (FPRL2) have been characterized as series of receptors, for which the main endogenous ligand is Annexin A1 (ANXA1; Solito et al., [@B116]). These receptors bind with high affinity to N-formylated bacterial peptides. FPRs are expressed on several immune cells including leukocytes, monocytes, and microglia. Among them the FPRL-1 mediates the chemotactic activity of Aβ42 for mononuclear phagocytes and therefore appear to be pathophysiologically relevant in the AD (Iribarren et al., [@B45]). In addition, Aβ bound to FPRL-1 is rapidly internalized into the cytoplasmic region as ligand/receptor complexes in mononuclear phagocytes. This process may represent responses of host-defense aiming at the clearance of abnormally elevated, pathogenic Aβ. However, the Aβ interaction with FPRL-1 is clearly associated with cell activation (Cui et al., [@B22]) and the release of pro-inflammatory and neurotoxic mediators (Pan et al., [@B83]). Interestingly FPRL-1 is highly express in mononuclear phagocytes surrounding and infiltrating Congo red-positive plaques in AD patients' brain tissue (Le et al., [@B53]).

### Complement receptors

Complement receptors are one of the categories of cell-surface molecules on microglia that are upregulated in response to the activation of these cells (Liu and Hong, [@B59]). Aβ-induced complement activation leads to generation of C1q, C4, and C3 activation fragments around the plaques. Here microglia express complement proteins C1q, C3, and receptors C1qR, CR3, CR4, and C5aR, which support phagocytic uptake (Keene et al., [@B49]). Inhibition of the complement system results in an increase of Aβ plaque formation and neurodegeneration in AD transgenic mice (Shen and Meri, [@B113]).

In contrast, lack of C1q in mice models of AD results in decrease pathology (Hafer-Macko et al., [@B39]). This indicates that one mechanism by which microglia could recruit further reactive cells to the site of a plaque and cause neurotoxic damage is by activating the classic complement pathway and the inflammatory machinery associated with it (pro-inflammatory cytokines, oxidative products) through production of C1q (McGeer and McGeer, [@B71]; Bonifati and Kishore, [@B11]).

The demonstration that the peripheral benzodiazepine receptor is upregulated in activated microglia led to the development of a ligand, \[^11^C\](R)-PK11195, which binds to this receptor also known as the 18-kDa translocator protein (TSPO). Extensive amyloid deposition and microglial activation can be demonstrated in the same group of AD patients *in vivo* by PET using \[^11^C\]PK11195 and a negative correlation between microglial activation and levels of cognition has been reported. Both amyloid deposition and microglial activation can be detected *in vivo* with PET in around 50% of patients with MCI. However, amyloid deposition and microglial activation are not necessarily correlated in MCI suggesting both can occur in the absence of the other (Okello et al., [@B81]; Sastre et al., [@B109]). On the other hand, a significant age-dependent increase in specific \[^3^H\](R)-PK11195 binding was also demonstrated in a transgenic mouse model of AD (TASTPM: APPswxPS1M146V; Roberts et al., [@B103]). This was consistent with immunohistochemical data showing age-dependent increases in CD68 immunoreactivity co-localized with Aβ deposits. CD68 is a 110-kDa transmembrane glycoprotein, expressed by monocyte/macrophage lineages and serves as a marker for microglia. Interestingly, an antibody to human TSPO revealed induction of TSPO-positive microgliosis by tau fibrils in tauopathy brains. In addition, in transgenic PS19 mice, carrying the P301S Tau mutation, radiolabeling of TSPO with \[^11^C\]AC-5216 was linearly proportional to the amount of phospho-tau immunolabeling (Maeda et al., [@B64]). The results of that study indicated that TSPO immunoreactivities are associated with NFTs, neuropil threads, and plaque neuritis rather than Aβ deposits. All together, the analysis of microglia by PET in AD and MCI patients plus the studies of microglial activation over time in animal models suggest that microglia activation occurs before Aβ deposition and correlates better with cognitive deficits and tau phosphorylation.

Microglial activation in different stages of AD
-----------------------------------------------

It has been hypothesized that early microglial activation in AD delays disease progression by promoting clearance of Aβ before formation of senile plaques. It is conceivable that glial activation is protective early in the disease (Wyss-Coray et al., [@B127]; Maragakis and Rothstein, [@B66]; Wyss-Coray, [@B126]). In fact, studies have shown that blood derived macrophages (BMDM) are able to efficiently eliminate amyloid and confer neuroprotection by secretion of growth factors such as the glia-derived neurotrophic factor (GDNF), which are potentially beneficial to the survival of neurons (Liu and Hong, [@B59]). Activated microglia in early stages of AD can reduce Aβ accumulation by increasing its phagocytosis, clearance, and degradation (Frautschy et al., [@B31]; Qiu et al., [@B96]). The mechanism by which Aβ is phagocytosed depends on the physical properties of Aβ and whether it is soluble or fibrillar. Secreted Aβ1-40 and Aβ1-42 peptides are constitutively degraded by neprilysin and the insulin degrading enzyme (IDE), a metalloprotease released by microglia and other neural cells, whose enzymatic activity is enhanced by inflammatory events, such as LPS stimulation (Qiu et al., [@B97]).

In later stages, with persistent production of pro-inflammatory cytokines, microglia lose their protective effect (Hickman et al., [@B43]; Jimenez et al., [@B47]) and may become detrimental through the release of cytokines and chemokines (Hickman et al., [@B43]). These inflammatory mediators modulate immune and inflammatory function and may also alter neuronal function. In addition, microglia from old transgenic mice have a decrease in the expression of the Aβ-binding SR-A, CD36 and RAGE, and the Aβ degrading enzymes IDE, neprilysin, and matrix metalloprotease 9 (MMP9), compared with wild-type controls (Hickman et al., [@B43]). Therefore, all the evidences support the idea that over-activated microglia could cause uncontrolled inflammation that may drive the chronic progression of AD by exacerbating Aβ deposition and stimulating neuronal death (Mrak and Griffin, [@B73]; Gao and Hong, [@B33]). This concept constitutes the "Neuroinflammatory hypothesis."

By comparison, the "Microglial dysfunction hypothesis" stipulates that rather than an increase of inflammatory function there is a loss of the microglial neuroprotective function in AD (Polazzi and Monti, [@B95]). Research has shown that the phagocytic abilities of microglia are altered in aging and impaired in neurodegenerative diseases. Therefore this "senescent" or dystrophic microglia can also contribute to the onset of sporadic AD (Streit et al., [@B119], [@B117]).

In addition, other studies have shown that inadequate recruitment of blood monocytes with aging might be a critical event that leads to disease onset. Because the dynamics of the local and systemic inflammatory response may vary with aging and stage of the disease, this would important for the outcome of immunosuppressive treatments (Schwartz and Shechter, [@B112]).

Studies with animal models have provided controversial data regarding the role of microglia in AD. Experiments crossing APP animal models with Iba1-TK mice, leading to nearly complete ablation of microglia, did not display differences in plaque formation (Grathwohl et al., [@B37]). These results suggest that microglia may not have a direct role on Aβ deposition, but affect neuronal function. These results also reinforce the role of blood monocytes, which may support the phagocytic function of microglia. However, another study, using two-photon microscopy, performed in triple-transgenic mice crossed with the microglial chemokine receptor CX3CR1 knockout mouse, revealed that microglia is involved in neuron elimination, indicated by locally increased number and migration velocity of microglia around lost neurons (Fuhrmann et al., [@B32]). Microglia were recruited to the neuron before and not after the elimination of the neuron. Furthermore, CX3CR1 knockout prevented neuronal loss, indicating that neuronal loss depends on the communication between neurons and microglia (Fuhrmann et al., [@B32]).

Microglia as target for AD therapy
----------------------------------

### Anti-inflammatory drugs

Microglia associated with the senile plaques is thought to be a potential target of non-steroidal anti-inflammatory drugs (NSAIDs). A study by Mackenzie and Muñoz ([@B63]) carried out in non-demented patients showed that those treated with NSAIDs had three times less activated microglia as non-treated controls. These data have been confirmed by *in vivo* treatment with NSAIDs such as ibuprofen in mouse models of AD, which have shown decreases in microglial activation and in inflammatory mediators such as iNOS, cyclooxygenase (COX), and cytokines (Lim et al., [@B58]; Heneka et al., [@B41]). Experiments performed using cultured microglia have revealed that incubation with NSAIDs decreased the secretion of pro-inflammatory cytokines and may increase Aβ phagocytosis (Lleo et al., [@B60]). However, the reduction of activated microglia and astroglia by NSAIDs was not significant in AD patients, indicating an age or stage dependent difference in the glial response, i.e., in their activation rate (Alafuzoff et al., [@B2]). Microglia in aged or diseased brains are primed and usually behave differently to those in younger individuals (Gao and Hong, [@B33]). Thus, it is likely that microglia do not respond equally to anti-inflammatory therapy in old age and therefore, treatment of patients with NSAIDs in advanced stages of the disease may not produce any benefit. In this regard, NSAIDs have been shown to have beneficial effects in young individuals with robust immune systems. In aged patients, these drugs may affect the weak systemic immune response of the patients, exacerbating the local damage by eliminating the capacity of the immune system to introduce disease-modifying factors to the inflamed area (Sastre and Gentleman, [@B106]) (Figure [2](#F2){ref-type="fig"}).

![**Different effects of NSAIDs on microglia**. The response to NSAIDs may differ depending on whether they are used in early stages of disease, in which microglia present an alternatively activated phenotype compared with late stages which is associated with a classical microglia phenotype. (Adapted from Sastre and Gentleman, [@B106]). Abbreviations: ROS, reactive oxygen species; NOS2, same as iNOS; IDE, insulin degrading enzyme; SC, scavenger receptors.](fphar-03-00014-g002){#F2}

A potential downstream target of some NSAIDs such as ibuprofen, indomethacin, and naproxen is the peroxisome proliferator-activated receptor-γ (PPAR-γ; Lehmann et al., [@B55]; Willson et al., [@B125]). Several PPAR-γ activators including NSAIDs, drugs of the thiazolidinedione class, and the natural ligand prostaglandin J2 (15d-PGJ2) have been shown to be able to inhibit the β-amyloid-stimulated secretion of pro-inflammatory products by microglia and monocytes responsible for neurotoxicity and astrocyte activation (Combs et al., [@B19]). Furthermore 15d-PGJ(2) caused microglial death, which terminates brain inflammation (Yang et al., [@B130]).

Interestingly, anti-TNFα treatment reduced Aβ and Tau phosphorylation in transgenic mice. Treatment with the antibody against TNF-α Infliximab increased the number of CD11c-positive dendritic-like cells and the expression of CD11c. These data suggested that the CD11c-positive dendritic-like cells might contribute to the Infliximab-induced reduction of AD-like pathology (Shi et al., [@B114]).

Therapeutic vaccination with Aβ antibodies in mice evidenced the Fc-mediated uptake and clearance of Aβ antibody complexes by local activated microglia (Bard et al., [@B6]; Weiner and Selkoe, [@B123]). Therefore, it was proposed that microglial activation by active immunization might be a valid mechanism for clearance of senile plaques (Gelinas et al., [@B35]).

### Endogenous molecule for the control of microglia detrimental action

The major breakthrough in the therapy of neurodegenerative disease would be controlling the switch between the beneficial versus the detrimental microglia phenotype in order to control inflammation.

Because Aβ stimulates microglia phagocytosis with consequent release of toxic factors, many studies have reported possible mechanism of action implicating receptors on microglia surface. In this regard, therapeutic agents that are able to disrupt the interaction between Aβ42 and FPR may prove beneficial in the treatment of AD.

We have recently published data providing strong indication for a protective role of a protein called annexin A1 (ANXA1), a glucocorticoid anti-inflammatory mediator in the peripheral system (Perretti and D'Acquisto, [@B87]). ANXA1 plays a key role in ensuring the effective and selective removal of apoptotic neuron-like cells under inflammatory and non-inflammatory conditions which is a ligand for FPRL-1 receptor (McArthur et al., [@B68]).

Our studies have shown that ANXA1 is upregulated in human microglia in AD, supporting a possible role for the protein in regulating the microglial response to amyloid plaques and inflammatory response in neurodegeneration. This view is strongly supported by further findings in which recombinant ANXA1 administration *in vitro* suppress microglial activation following an inflammatory challenge (McArthur et al., [@B68]).

The identification of microglial FPRL-1 as a receptor for ANXA1, together with our identification of strong expression of ANXA1 in neuritic plaque-associated microglia in AD, suggests a fascinating connection with published data indicating a link between Aβ and FPRL-1 (Heurtaux et al., [@B42]). Microglia have clearly been shown to phagocytose Aβ through this receptor, but they appear unable to digest this protein, leading to persistent internalization of Aβ/FPRL-1 complexes and culminating in intracellular fibril formation and apoptosis (Pan et al., [@B83]). The binding of ANXA1 to FPRL-1 in microglia may thus be able to disrupt the interaction of the receptor with Aβ, potentially being of significant benefit in the treatment of AD (Figure [3](#F3){ref-type="fig"}).

![**Hypothetical annexin A1- FPRLI mechanism of action in microglia**. Annexin A1 binds to FPRL-1 triggering an SOS signaling limiting microglia response to Aβ and preventing a constant uptake and apoptosis, altering microglia pro-inflammatory phenotype.](fphar-03-00014-g003){#F3}

Conclusion
==========

Microglia effects on AD seem to have double component. On one hand their activation seems to be neuroprotective at early stages of the disease but at older ages and in severely ill patients the effects could be counterproductive. There is therefore the need to investigate the changes in phenotype of resident microglia and how they react to anti-inflammatory therapy over age. In addition, it would be relevant to determine the role of monocyte-derived macrophages along different stages of the disease. One could speculate that the use of BMDM, which are more effective at degrading Aβ could compensate the defective functions of senescent resident microglia (Davoust et al., [@B23]).

In the future, the combined use of amyloid and microglial imaging should allow one to determine how different anti-amyloid strategies exert their therapeutic effects. Follow-up and further imaging of patients at risk of developing AD with radiotracers that bind to the TSPO/peripheral benzodiazepine receptor will enable a better understanding of both the pattern and the time course of microglial activation and will also provide the opportunity to monitor the pathophysiological effects of anti-inflammatory agents in these patients *in vivo*.
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